Type 2 diabetes is associated with a higher rate of ventricular arrhythmias compared with the non-diabetic population, but the associated myocardial gene expression changes are unknown; furthermore, it is also unknown whether any changes are attributable to chronic hyperglycaemia or are a consequence of structural changes. r What is the main finding and its importance?
Introduction
Type 2 diabetes is becoming increasingly common worldwide and is associated with ischaemic heart disease and other macrovascular diseases. A cardiomyopathy related to chronic damage from hyperglycaemia has been described and termed 'diabetic cardiomyopathy' (Miki et al. 2013) . Higher rates of cardiac arrhythmias are observed in diabetes (Suarez et al. 2005) , and specifically in type 2 diabetes (Panova & Korneva, 2006) , compared with control patients without diabetes, both in patients with established coronary artery disease and in the general population (Movahed et al. 2007) .
The mechanisms predisposing to increased arrhythmogenesis in patients with type 2 diabetes are complex, but it does seem to be independent of coronary artery disease and cardiac ejection fraction (Junttila et al. 2010; Eranti et al. 2016) . Suggested potential disease-specific mechanisms from animal studies include an abnormal response to catecholamines (Frier et al. 2011) , inhibition of the ERG channel (Zhang et al. 2006) or alterations in cardiac ryanodine receptor number/function, as a result of chronic hyperglycaemia (Yaras et al. 2005) . In addition to effects of type 2 diabetes, the treatment of this condition can potentially be arrhythmogenic, with hypoglycaemia as a result of treatment with insulin or sulfonylureas being linked to arrhythmias (Lindström et al. 1992) , and specifically as sulfonylureas also have an effect on cardiac K + channels (Brady & Terzic, 1998) . In addition to pro-arrhythmic cellular and channel-level changes, arrhythmogenic structural changes, such as left ventricular (LV) hypertrophy and myocardial fibrosis, are common in type 2 diabetes (Karagueuzian, 2011) . Cardiac hypertrophy and fibrosis in the absence of hypertension or ischaemia can be seen in other cardiac diseases, such as valvular aortic stenosis (Weidemann et al. 2009) .
In this study, we measured the gene expression of key ion channels and associated molecules to investigate what changes might underpin the higher arrhythmic event rate in patients with type 2 diabetes and how, using mathematical modelling based on gene expression data, the action potential (AP) might be affected. We undertook this study in patients with aortic stenosis, a condition that also causes LV hypertrophy and myocardial fibrosis, to try to identify changes specific to diabetes.
Methods

Ethics approval
The study was approved by the NHS Liverpool East Research Ethics Committee (11/NW/0290) and conducted in accordance with the principles established in the Declaration of Helsinki sixth version. The study was not registered in a research database, and this is an exception to clause 35 of the Helsinki declaration. All participants gave written informed consent.
Study population
Criteria for inclusion were patients >18 years of age, male or postmenopausal female, with or without type 2 diabetes, undergoing aortic valve replacement for aortic stenosis (calculated aortic valve area of ࣘ1 cm 2 ), with preserved left ventricular function defined by European Society of Cardiology and an ejection fraction of >50% (Nagueh et al. 2009 ) at Liverpool Heart and Chest Hospital.
Exclusion criteria were patients in atrial fibrillation, patients with type 1 diabetes, chronic renal impairment with an estimated glomerular filtration rate of <30 ml min −1 (Levey et al. 1999) , need for surgery in addition to the aortic valve replacement other than coronary artery grafting, other conditions that may cause LV impairment, such as regurgitant valvular lesions graded moderate or more, thyroid dysfunction and excess alcohol consumption.
Our control group had their available medical records reviewed for previous random blood sugar measurements and fasting samples. All patients in the control group had not had any abnormal fasting glucose measurements (>7.0 mmol l −1 ) or random samples >11.0 mmol l −1 with typical symptoms (American Diabetes Association, 2015) .
Patients had their height, weight and waist circumference measured, body mass index calculated, and patients with diabetes had their most recent glycated haemoglobin (HbA 1c ) recorded using the International Federation of Clinical Chemistry and R. Ashrafi and others Laboratory Medicine (IFCC) method (John et al. 2007 ). In addition, medications for each patient's diabetes treatment and any cardiac specific medication were recorded.
ECG assessment
All patients had a standard 12-lead ECG and their QT interval measured using the Bazett formula (Luo et al. 2004) . All patients underwent signal-averaged ECG monitoring (SAECG) following a 10 min rest in the supine position using a MAC 500 machine (GE Healthcare, Madison, WI, USA) before cardiac surgery. Digital filtering was performed with a 40-250 Hz bandpass bidirectional filter, and averages were taken over 250 beats with maximal acceptable noise of 0.5 μV.
All ECGs were analysed for late potentials (Okin et al. 1995) .
Echocardiography
Before cardiac surgery, all patients underwent twodimensional echocardiography study using commercially available vivid Q, vivid 7 (GE Healthcare, Hatfield, UK) and IE 9 (Phillips, Guildford, UK) systems and a 3.5 MHz transducer.
Assessment of strain was made using offline software (EchoPAC; GE Healthcare), and measurements were made in apical two-, three-and four-chamber view for global longitudinal strain, with values from each segment being averaged for a mean score. Circumferential and radial strain were measured using a mean score from six segments in the parasternal short axis at the mid-wall level as previously described (Hung et al. 2010) .
Several studies have reported that myocardial fibrosis can be associated with higher rates of arrhythmias (de Jong et al. 2011) , and it is widely reported in patients with diabetes (Picatoste et al. 2013) ; when trying to allow for this potential confounder we have tried to match our experimental group with a control group also reported to exhibit signs of myocardial fibrosis (patients with aortic stenosis). Myocardial fibrosis can be assessed by cardiac magnetic resonance imaging (MRI) or histological examination, but there have been studies in aortic stenosis (Weidemann et al. 2009 ) and diabetes (Ng et al. 2012) looking at the correlation of two-dimensional speckle tracking strain rate using echocardiography with fibrosis in patients with normal ejection fraction values. A global contrast-enhanced myocardial T 1 mapping time (spin lattice relaxation time) on MRI of <500 ms has been shown to be correlated with fibrosis (Iles et al. 2008) , and a T 1 mapping time of <500 ms has been correlated with a global longitudinal strain of <−18% using two-dimensional speckle tracking echocardiography (Ng et al. 2012) .
Left ventricular biopsy
Patients had a biopsy sample taken by a consultant cardiothoracic surgeon through the LV apex in the position normally used for transapical aortic valve implantation at the time of aortic valve replacement surgery. The biopsy was performed using a single TRUCUT TM biopsy needle (Cardinal Health, Dublin, OH, USA) immediately before the insertion of cardioplegia solution. The sample was then taken and immediately placed in physiological Hartmann's solution (Baxter Healthcare, Newbury, UK) before immediate transfer to the laboratory for processing. All samples were mounted in OCT (optimal cutting temperature compound; Tissue Tek, Fisher Scientific, Loughborough, UK) before flash freezing in liquid nitrogen.
RNA isolation and quantitative polymerase chain reaction (qPCR) measurement
Briefly, from frozen tissue, RNA was isolated using the mirVana RNA isolation kit (Life Technologies, Paisley, UK) and amplified to cDNA using high-capacity RNA to cDNA for quantitative PCR (Applied Biosystems, Warrington, UK).
Quantitative PCR was performed using custom preloaded low-density Taqman array microfluidic cards, which contain multiple specific individual custom gene primer sequences and universal Mastermix II and a 7900HT fast real-time PCR system (all from Applied Biosystems). Samples were run with one control sample with distilled water for every gene target run per card. Expression of the gene targets was referenced to an abundant housekeeping gene, 18S in this study. We chose 18S as the housekeeping gene for this study based on previous experimental work (Sharma et al. 2004; Pérez et al. 2007 ) and preliminary animal data from a previous study performed within the department (Ashrafi et al. 2016) . Initial mRNA expression data were logarithmically transformed using the 2 − C T method as previously described (Livak & Schmittgen, 2001 ).
The list of target genes analysed with their context sequences is given in Table 1 .
Mathematical modelling of the action potential
In this study, we used the O'Hara-Rudy dynamic model (O'Hara et al. 2011) , which is a mathematical model simulating the human ventricular myocyte AP transmurally, to look at the effect of the changes in mRNA seen in the diabetes group. This model has been used in a wide variety of experiments and experimental conditions, with good validation (Bartos et al. 2013) . Using this model, channel conductance was scaled according to the measured average ratio of mRNA between the control and the diabetes groups. In the control and the diabetes groups, the models were run for a 5 s period to obtain steady-state conditions, before a sequence of external stimulus pulses (with an amplitude of 0.8 nA, duration of 5 ms and frequency of 1 Hz) were applied to evoke an AP. To evaluate the relative role of each of the remodelled ion channels, simulations were also performed by looking at the change to each individual ion channel alone.
Statistical analysis
Patient characteristics are shown as means and 95% confidence intervals. Experimental data are reported as means ± SD. All single-variable experimental work was analysed for significance using Student's unpaired t-test, comparing the control group with the type 2 diabetes group. As previously described, multiple Student's t tests with a Benjamini-Hochberg false discovery rate correction (ࣘ0.05) were used to assess the significance of the mRNA expression results (Tsay et al. 2015) . Results were taken as being significant with a P value of ࣘ0.05.
Results
Patient characteristics
A summary of patients recruited and their mean baseline information is shown in Table 2 , and there were no significant differences in baseline patient characteristics (P = n.s.). Patient medication breakdowns are shown in Table 3 , with no significant difference in medication usage between groups for β-blockers, angiotensin-blocking drugs (angiotensinconverting enzyme blocker/angiotensin receptor blocker) or statin use.
ECG assessment
Standard ECG assessment of the corrected QT intervals revealed a higher mean QT interval in the diabetes group (n = 9; 467 ± 2.32 ms) compared with the control group (n = 7; 451 ± 5.26 ms; P = 0.011). The SAECG assessment of our two groups yielded one patient in each group with a positive SAECG for late potentials. Control  9  3  5  0  0  0  4  Diabetes  7  3  5  0  4  2  6 Abbreviations: ACE, angiotensin-converting enzyme; and ARB, angiotensin receptor blocker. 
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Echocardiographic assessment
Our results showed that both study groups were comparable in terms of traditional measurements of LV function (ejection fraction) and LV wall thickness (septal width). Both groups showed significant hypertrophy of the LV septum when compared with reference values (Lang et al. 2005) , and the LV hypertrophy seen was felt to be attributable to pressure loading from the aortic stenosis and therefore by European Society of Cardiology guidance is appropriate and not suggestive of hypertrophic cardiomyopathy (Authors/Task Force et al. 2014) . However, longitudinal function was lower in the diabetes group (n = 9) measured using mitral annular longitudinal excursion (MAPSE), and there was greater left atrial size compared with the control group (n = 7), consistent with other studies (Table 4 ; Ha et al. 2007) . Speckle tracking strain analysis provides a more detailed measurement of myocardial function and pathology (Gorcsan & Tanaka, 2011) because it measures myocardial deformation using tissue tracking, and this is more accurate than looking at simple movement (MAPSE) or volume change (ejection fraction), to truly understand the tissue function of the myocardium. Strain analysis was undertaken between the groups to look for subtle LV dysfunction or pathology and was assessed in the circumferential, radial and longitudinal directions. Global circumferential strain in the diabetes group was nearly 50% lower (11.6 ± 6.2) compared with the control group (−20.5 ± 1.9; P < 0.01) and, likewise, longitudinal strain was lower in the diabetes group (−12.7 ± 1.09) compared with the control group (−16.5 ± 0.75; P = 0.013). As myocardial fibrosis progresses, replacing tissue between myocytes, this leads to reduced myocardial deformation, which can be measured using strain analysis. In our control and diabetes groups, we observed longitudinal strain measurements (below −18%) in the range associated with myocardial fibrosis in diabetes (Ng et al. 2012 ) and in aortic stenosis alone when a normal ejection fraction has been recorded in patients without diabetes (Weidemann et al. 2009 ). These figures suggest that our diabetes group and control group are well matched with regard to potential fibrosis.
Ventricular mRNA expression
Results from the gene expression part of the study are summarized in Table 5 , with significant increases in the diabetes group for SLC8A1, KCNJ2 and KCNJ5. There was a reduction in the diabetes group in the expression of KCNH2 and KCNJ3.
Action potential modelling
Using the mRNA results discussed above, we used the relative percentage difference in gene expression to alter current density in the diabetes group (Table 6 ) and using the O'Hara-Rudy dynamic model we were able to produce APs for the control and diabetes group at both the endocardial and epicardial levels. Figure 1 shows a modelled AP from the endocardium (Fig. 1A) and epicardium (Fig. 1B) . In both modelled wall layers, changes in the diabetes group produced increased amplitudes of the AP, elevation in the plateau phase and prolongation of the AP. We were also able to show at the endocardial layer modelled creation of an early after-depolarization (EAD) at the plateau phase, the trigger for many types of ventricular arrhythmias.
In Fig. 2A (for the endocardium) and B (for the epicardium), the effects of all the individual currents are modelled to identify which of the currents are responsible primarily for the AP prolongation and EAD generation we have seen at the endocardial layer. Most of the currents modelled individually do not have much input into the AP prolongation suggested above, apart from I NaCa encoded by SLC8A1 and I Kr coded by KCNH2. There was also a very slight acceleration in the final phase of repolarization, creating a steeper rate of descent in the diabetes group, which appeared to be created by the modelled increase in I K1 .
Discussion
In this study, we report, for the first time, lower LV expression of KCNH2 and increased SLC8A1 in humans with type 2 diabetes and aortic stenosis (compared with non-diabetic patients with the same condition), with the corresponding clinical sequelae of prolongation of the QT interval. Although QT interval elongation in humans with type 2 diabetes (Rutter et al. 2002) and alteration in KCNH2/SLC8A1 mRNA cardiac expression in animal models of diabetes (Hattori et al. 2000; Zhang et al. 2007) have been reported previously, the combination has not been reported in humans before. The other novel aspect of our study was the use of a control group with a condition other than diabetes that produces LV hypertrophy and myocardial fibrosis (aortic stenosis; Weidemann et al. 2009) , and this helps to support the theory that gene expression changes in our diabetes group were as a result of diabetes or hyperglycaemia not merely a final common downstream pathway linked to fibrosis and LV hypertrophy. The major gene expression change found was a marked reduction in ventricular expression of ERG mRNA, which encodes the pore-forming subunit of the I Kr channel, the major outward K + delayed rectifying current, with a marked prolongation of the modelled AP. I Kr is a K + voltage-gated current, which begins to be activated as the membrane potential drops at the end of phase 2, the plateau phase, reaching a current maximum at −40 mV during phase 3, allowing for a large outward current. I Kr is rapidly inactivated at positive voltages, maintaining the AP plateau, but is also quick to recover from inactivation, allowing the generation of the large outward current, which is largely responsible for phase 3 in humans and limits the AP duration (Vandenberg et al. 2012 ).
Our AP modelling shows that downregulation of ERG creates EADs at the endocardial level, which has been reported previously in long-QT syndromes with normal cellular coupling (Viswanathan & Rudy, 2000) , this being thought to be attributable to reactivation of I CaL , created by extension of the plateau phase because of reduced ERG. The endocardium seems to be more vulnerable to EADs than the epicardium, predominantly as the sharper electrical gradient between the epicardium and mid-myocardium allows formation of a 'sink' for excess current in the epicardium, reducing EADs in the mid-and epicardial layers (Viswanathan & Rudy, 2000) . Reduced ERG expression and/or ERG blockade clinically in arrhythmogenesis (Gong et al. 2007 ) has been reported previously, particularly in patients with diabetes (Zhang et al. 2006) . In previous studies looking at ERG downregulation, it has been shown that both myocardial hypertrophy (Hu et al. 2011 ) and myocardial fibrosis (Chu et al. 2012) are associated with reduced ERG, and it was not clear that diabetes had a specific effect on ERG expression within the myocardium or whether downregulation of ERG was a function of hypertrophy or fibrosis. As discussed above, by comparison with a similar control group it was found that there seems to be a specific effect of diabetes on ERG expression within the myocardium, and this may go some way to explaining the higher arrhythmia rates in patients with diabetes, particularly in the light of the modelled EAD formation and longer QT intervals seen. As well as reduced ERG expression, we also observed NCX1 overexpression, which would prolong the AP as was shown in our modelling, and this, combined with reduced I Kr , leads to EAD generation at the endocardial level.
As well as EAD formation, prolongation of the AP leads to stimulation of NCX1 forward mode and generation of a late transient inward current, I TI , in phase 3 of the AP, which is more likely with a sharper membrane potential drop as we have observed in our modelled AP (largely the result of increased I K1 ) and in patients with hyperglycaemia secondary to increased Na + concentrations. I TI can cause delayed after-depolarizations if the current generated is large enough.
Expression of NCX1 has been seen to be increased in LV hypertrophy (Menick et al. 2013) , and by comparing our diabetes group, who would be expected to have increased LV mass, with a control group with LV hypertrophy (as a result of aortic stenosis) we were able to show support for the theory that diabetes specifically does seem to be associated with NCX1 overexpression.
The role of NCX1 in the AP has been the subject of much discussion, and findings have been variable in different experiments owing to the forward and reverse modes of NCX1. It has been shown previously in failing canine hearts with high Na + that NCX1 acts in the outward mode to shorten the AP, but in low-Na + states it acts in the inward mode to prolong the AP (Armoundas et al. 2003) . In similar pathological states with hypertrophy and fibrosis, increased NCX1 has been shown to prolong repolarization at the end of the AP , and overexpression of NCX1 in diabetes has been shown in animal models to prolong the AP and increase systolic function (LaRocca et al. 2012) . There has been conflicting data on NCX1 expression in the streptozocin rat model, with several papers showing a reduction in NCX1 expression (Zhao et al. 2014; Akhtar et al. 2016) . In these studies, the studied rats were comparatively young, with significantly lower body weights and left ventricular function, and our results may reflect a different diabetes process related to insulin resistance and obesity.
Contrary to the above changes in SLC8A1/KCNH2, the diabetes group had an upregulation of KCNJ2, the gene responsible for the main component of the I K1 channel, which sets the resting membrane potential. Our AP modelling has shown that this probably has only a small effect on the AP, most obviously in acceleration in phase 3 of repolarization to give a sharper terminal part of the AP, and acts to limit the AP duration. The role of I K1 in this setting is difficult to be certain of, but it is possible that the increase in mRNA may be compensatory in the face of the AP prolongation caused by I Kr and NCX1.
The final significant mRNA changes observed were in KCNJ3 and KCNJ5, with reduced expression of KCNJ3 in the diabetes group but increased KCNJ5. KCNJ3 codes for a tetrameric, acetylcholine-activated inward-rectifying K + channel (I KACh ) that is expressed in the atria and ventricles. Most prior experimental work has been on the atrial effects of I KACh , and we did not incorporate this into our biophysical model because the channel is only active with acetylcholine. In atrial studies, inhibition of the I KACh channel resulted in prolongation of the AP in the atria (Bingen et al. 2013) . Whether this effect would be reproduced in the ventricle would require physiological testing but seems in keeping with the prolonged AP we have modelled. KCNJ5 codes for the remaining two of the four subunits of the I KACh channel and has stretch-related properties, and in high-stretch situations inhibits channel function (Tamargo et al. 2004) . This upregulation of the stretch-sensitive subunits would suggest, that the higher LV filling pressures commonly seen in diabetes may present a mechanism for further I KACh channel inhibition, which would merit further physiological testing.
As with many studies similar to ours, a major limitation is the small sample size, and before extrapolation to the wide human population with diabetes, larger studies would be needed. In our study population, we have had a relatively older group of patients with mean ages >70 years R. Ashrafi and others in both groups and fewer women than men, which is an important limitation because age (Ocorr et al. 2007; Rabkin, 2014) and sex (Cheng, 2006) are associated with differences in cardiac repolarization. A larger study would be needed to assess the importance of these factors in the changes we have observed and whether the results could be extrapolated to younger people and by gender specifically. One area of potential limitation is in the medication background of our diabetes group, as sulphonylureas have been shown to have some effect on the cardiac ATP-dependent K + channel (Aronson et al. 2003) , and although this channel was not assessed in the present study, some overlap with the other K + channel genes studied here cannot be excluded. Likewise, given that metformin has wide-ranging effects on growth factors and an antifibrotic effect (Bai et al. 2013) , some reduction in the gene expression changes we may have seen in the study could have occurred.
In this study, we used a combination of QT prolongation on the ECG with AP modelling and mRNA changes to look at the effect of diabetes, and confirmatory protein measurement of the mRNA results with direct electrophysiology measurement of myocytes from the diabetic human hearts would be required for confirmation of the effects reported here. Review of the existing literature currently suggests that there is reasonable correlation of mRNA with protein measurements (Ellinghaus et al. 2005; Brioschi et al. 2009; Ferdous et al. 2016) and with electrophysiological measurements (Howarth et al. 2009 ), but that correlation is not universal, and post-transcriptional mechanisms do play an important role in multiple settings (Panguluri et al. 2013) , something that would need further analysis.
Conclusion
Patients with type 2 diabetes have a prolonged QT interval compared with a control population with similar levels of LV hypertrophy, and this is associated with gene expression changes likely to cause AP prolongation. These findings may explain, in part, the higher rates of ventricular arrhythmias seen in patients with diabetes.
